Study of CD388 for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications
Clinical trial NCT06609460 · COMPLETED
Trial details
- NCT number
- NCT06609460
- Sponsor
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-09-20
- Primary completion
- 2025-10-09
- Enrollment
- 5071
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.